Sabitlenmiş Tweet

We’re excited to share that our INTEGRA-D Clinical Trial has successfully met the primary efficacy endpoint, as presented at #HRS2025. Learn more about this study evaluating the combination of CCM® therapy and ICD in a single device to help more patients: bit.ly/4d1eXw0

English















